Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation

World Health Organization (WHO) Lai, 2007, The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points, Ann Intern Med, 147, 58, 10.7326/0003-4819-147-1-200707030-00010 Lai, 2017, Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B, J Hepatol, 66, 275, 10.1016/j.jhep.2016.08.022 Inoue, 2019, The role of hepatitis B core-related antigen, Genes, 10, 357, 10.3390/genes10050357 Mak, 2018, Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection, Aliment Pharmacol Ther, 47, 43, 10.1111/apt.14376 Rokuhara, 2003, Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment, J Viral Hepat, 10, 324, 10.1046/j.1365-2893.2003.00437.x Wong, 2017, Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA, Liver Int, 37, 995, 10.1111/liv.13346 2017, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021 Mak, 2019, New biomarkers of chronic hepatitis B, Gut Liver, 13, 589, 10.5009/gnl18425 Kumada, 2013, Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis, J Hepatol, 58, 427, 10.1016/j.jhep.2012.10.025 Hosaka, 2019, Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues, Aliment Pharmacol Ther, 49, 457, 10.1111/apt.15108 Suzuki, 2019, Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma, Hepatol Res, 49, 51, 10.1111/hepr.13277 Shinkai, 2013, Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance, J Clin Microbiol, 51, 3484, 10.1128/JCM.00726-13 Kusumoto, 2020, Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma, J Hepatol, 73, 285, 10.1016/j.jhep.2020.03.009 Shinkai, 2017, Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay, Liver Int, 37, 1138, 10.1111/liv.13349 Kimura, 2002, Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load, J Clin Microbiol, 40, 439, 10.1128/JCM.40.2.439-445.2002 Kimura, 2003, New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA, J Clin Microbiol, 41, 1901, 10.1128/JCM.41.5.1901-1906.2003 Kimura, 2005, Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain, J Biol Chem, 280, 21713, 10.1074/jbc.M501564200 Aguiar, 2016, High functional stability of a low-cost HBV DNA qPCR primer pair and plasmid standard, Euroasian J Hepatogastroenterol, 6, 19 Wong, 2007, Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection, J Clin Microbiol, 45, 3942, 10.1128/JCM.00366-07 Rokuhara, 2005, Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection, J Gastroenterol Hepatol, 20, 1726, 10.1111/j.1440-1746.2005.04087.x Wong, 2017, Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA, Liver Int, 37, 995, 10.1111/liv.13346 Chuaypen, 2016, Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B, Liver Int, 36, 827, 10.1111/liv.13046 Seto, 2014, Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B, Clin Microbiol Infect, 20, 1173, 10.1111/1469-0691.12739 Seto, 2012, Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay, Hepatol Int, 7, 98, 10.1007/s12072-012-9354-7 Corcuera, 2018, Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro, Antivir Res, 158, 135, 10.1016/j.antiviral.2018.07.011 Seto, 2016, Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy, Am J Gastroenterol, 111, 1788, 10.1038/ajg.2016.436 Iossa, 2019, Hepatitis B core-related antigen to detect hepatitis B virus (HBV) reactivation in heart transplant recipients with past HBV infection: a pilot study, Clin Transpl, 33, 10.1111/ctr.13574 Ning, 2018, Common and distinct capsid and surface protein requirements for secretion of complete and genome-free hepatitis B virions, J Virol, 92, 10.1128/JVI.00272-18 Yaginuma, 1987, Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA, Proc Natl Acad Sci U S A, 84, 2678, 10.1073/pnas.84.9.2678 Yoshida, 2021, Assay for hepatitis B core-related antigen identify patients with high viral load: systematic review and meta-analysis of individual participant data, Clin Gastroenterol Hepatol, 19, 46, 10.1016/j.cgh.2020.04.045